Viridian Therapeutics Stock Today
| VRDN Stock | USD 19.43 0.22 1.15% |
Performance0 of 100
| Odds Of DistressLess than 20
|
Viridian Therapeutics is selling at 19.43 as of the 30th of January 2025; that is 1.15 percent increase since the beginning of the trading day. The stock's open price was 19.21. Viridian Therapeutics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of June 2014 | Category Healthcare | Classification Health Care |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts. Viridian Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 79.21 M outstanding shares of which 11.63 M shares are at this time shorted by private and institutional investors with about 5.85 trading days to cover. More on Viridian Therapeutics
Moving together with Viridian Stock
Moving against Viridian Stock
| 0.5 | MLAB | Mesa Laboratories Earnings Call This Week | PairCorr |
| 0.46 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Viridian Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | MBA JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Viridian Metals Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsViridian Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Viridian Therapeutics' financial leverage. It provides some insight into what part of Viridian Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Viridian Therapeutics (VRDN) is traded on NASDAQ Exchange in USA. It is located in 221 Crescent Street, Waltham, MA, United States, 02453 and employs 94 people. Viridian Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.54 B. Viridian Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 79.21 M outstanding shares of which 11.63 M shares are at this time shorted by private and institutional investors with about 5.85 trading days to cover.
Viridian Therapeutics currently holds about 161.21 M in cash with (184.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66.
Check Viridian Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Viridian Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Viridian Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Viridian Therapeutics. Please pay attention to any change in the institutional holdings of Viridian Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Viridian Ownership Details
Viridian Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-09-30 | 2.4 M | |
| Tang Capital Management Llc | 2024-09-30 | 2.2 M | |
| Alliancebernstein L.p. | 2024-09-30 | 2.2 M | |
| Maverick Capital Ltd | 2024-09-30 | 2 M | |
| Driehaus Capital Management Llc | 2024-09-30 | 2 M | |
| Ecor1 Capital, Llc | 2024-09-30 | 2 M | |
| Vivo Capital, Llc | 2024-09-30 | 1.7 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.5 M | |
| Adage Capital Partners Gp Llc | 2024-09-30 | 1.2 M | |
| Fmr Inc | 2024-09-30 | 11.2 M | |
| Blackrock Inc | 2024-09-30 | 4.8 M |
Viridian Therapeutics Historical Income Statement
Viridian Stock Against Markets
Viridian Therapeutics Corporate Management
| Seth Harmon | Principal Accounting | Profile | |
| Anthony Casicano | Chief Officer | Profile | |
| Kristian MBA | Chief CFO | Profile | |
| Melissa Manno | Chief Officer | Profile | |
| Anthony Casciano | Chief Officer | Profile | |
| Jennifer JD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share | Quarterly Revenue Growth 0.194 | Return On Assets | Return On Equity |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.